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After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy,
they often recur as chemotherapy-resistant tumors, and this has been associated with
upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful
adjunct to chemotherapy treatment of these cancers. We performed a high-throughput
chemical screen for inhibitors of HDR from which we obtained a number of hits that
disrupted microtubule dynamics. We postulated that high levels of the target molecules of
our screen in tumors would correlate with poor chemotherapy response. We found that
inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking
and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells
and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment
strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for
TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is
important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer
chemotherapy and an important target for therapy.
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Introduction
DNA double-strand breaks (DSBs) are believed to be the most 
critical lesions induced by many cancer therapies, including che-
motherapy and ionizing radiation (IR). Homology-directed repair 
(HDR), or homologous recombination repair, plays an important 
role in tumor resistance to treatment because it repairs these 
breaks. Hence, the clinical ability to inhibit HDR may lead to 
improved outcome for patients undergoing DSB-inducing cancer 
therapy. On the other hand, defects in HDR result in genomic 
instability and increase carcinogenesis, explaining the fact that 
tumor cells in many aggressive cancers, including some forms of 
breast, ovarian, and pancreatic cancers, are defective in HDR (1). 
HDR defects are thought to be involved in the etiology of these 
cancers in such cases. As an example, women with germline muta-
tions in BRCA1, a tumor suppressor with crucial roles in HDR and 
maintenance of genome stability, have a high risk of developing 
breast and ovarian tumors. Since HDR is involved in repair of 
DNA DSBs and interstrand cross-links (ICLs), cells with defective 
BRCA1 are unable to repair these types of damage and display sen-
sitivity to DSB- and ICL-inducing agents, such as IR and nitrogen 
mustards (e.g., chlorambucil and cyclophosphamide).
Mutations in BRCA1 are particularly prevalent in triple- 
negative breast cancers (TNBCs), i.e., those that do not express 
estrogen receptor and progesterone receptor and lack overexpres-
sion or amplification of human epidermal growth factor receptor 
2 (HER2/NEU, or erbB2). TNBCs have a significant overlap with 
basal-like breast cancers (BLBCs), and the majority of BRCA1- 
related tumors are both triple-negative and basal-like (2, 3). These 
cancers are characterized by high genomic instability, fast growth, 
and early metastasis, and have the worst prognosis among breast 
cancer types. Sporadic TNBCs also display a genome instability 
phenotype and sensitivity to chemotherapy similar to those of the 
BRCA1-related TNBCs, suggesting that deficiency in BRCA1 or 
other DNA repair defects may also be involved in their etiology. 
In fact, promoter methylation and transcriptional inactivation 
of BRCA1, defects in DNA excision repair, and low expression of 
DNA repair genes from HDR, nucleotide excision repair, and Fan-
coni anemia pathways (4, 5) are observed in TNBCs.
Since TNBCs lack the expression of hormone receptors and 
do not overexpress HER2, no targeted therapy is available for 
these breast cancers, and standard DNA-damaging chemotherapy 
remains the main treatment of choice for TNBC/BLBC patients (2, 
3). On a positive note, as mentioned, early-stage TNBCs/BLBCs 
display high sensitivity to chemotherapy, likely due to DNA repair 
defects, and if they do not relapse within the first 3–5 years after 
chemotherapy, the risk of relapse at later times is significantly 
lower than for other types of breast cancer (6, 7). However, in 
an apparent paradox, tumors that present at late stage or have 
relapsed are very resistant to treatment and often display upreg-
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ure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/JCI87191DS1) (22). As a positive control, 
we chose to treat cells with 17-AAG (17-allylamino-17-demethox-
ygeldanamycin; see structure in Supplemental Figure 1B), an 
agent belonging to the geldanamycin family (23) that binds to the 
ATP-binding region of HSP90 and inhibits HDR by blocking the 
HSP90-dependent maturation of RAD51 and BRCA1 (24). Treat-
ment of cells with 17-AAG inhibited both gene conversion (Fig-
ure 1B and Supplemental Figure 1C) and IR-induced Rad51 foci 
formation (Figure 1C and ref. 24) in CHO AA8 cells, as well as in 
CHO irs1SF cells, which are defective in HDR because of loss of 
the Xrcc3 gene (Supplemental Figure 1D). Exposure to 17-AAG also 
significantly elevated chromatid-type aberrations after chloram-
bucil (Figure 1D and Supplemental Figure 1E). Notably, 17-AAG 
increased chlorambucil sensitivity of repair-proficient CHO AA8 
cells, but had no effect on the chlorambucil sensitivity of HDR- 
defective CHO irs1SF cells (Figure 1E), suggesting that 17-AAG 
potentiates chlorambucil cytotoxicity through inactivation of 
HDR. This conclusion is further supported by the knockdown of 
the HDR mediator Rad51C in AA8 cells (Supplemental Figure 
1F): both knockdown of Rad51C and pretreatment with 17-AAG 
separately increase the sensitivity of AA8 cells to chlorambucil, 
while 17-AAG does not further increase chlorambucil sensitivity 
in cells with shRad51C knockdown. Combined, our data suggest 
that 17-AAG can be used as a positive control in the screen to iden-
tify agents compromising HDR. As expected, in our library screen 
of known compounds for HDR inhibition (see Methods), 17-AAG 
(and other geldanamycins) came up among the positive hits. Inter-
estingly and unexpectedly, our screen also identified agents that 
disrupt tubulin dynamics and endocytosis (Figure 2A).
A high-throughput screen reveals that microtubule-binding agents 
impair HDR. We screened chemical libraries of more than 130,000 
diverse compounds. We found 640 hits in the primary screen using 
the chlorambucil sensitivity assay, of which 46 were confirmed in a 
dose-response assay to indeed increase cellular sensitivity to chlo-
rambucil. These 46 compounds were further tested in the gene 
conversion assay. To separate inhibitors of HDR from compounds 
that reduce GFP expression because of their cytotoxicity or cyto-
static effects, we plotted gene conversion levels versus cell growth 
(Figure 2B). Inhibition of HDR at concentrations compatible 
with cell survival should significantly reduce the number of GFP- 
positive cells. Therefore, HDR inhibitors should cluster in the 
lower left (low gene conversion and high survival) quadrant of the 
chart (dark gray symbols). As expected, this quadrant contained 
17-AAG, and also mirin and curcumin, 2 other compounds previ-
ously reported to inhibit HDR (25, 26). All 3 compounds reduced 
I-SceI–induced HDR at concentrations compatible with cell survival 
(Figure 2B). In agreement with the results of our screen using the 
known compound libraries (Figure 2A), the “low gene conver-
sion and high survival” quadrant contained several compounds 
from a family related to a naphthopyran, LY290181 (Supplemen-
tal Figure 2, A and B), which binds microtubules (27, 28). These 
hits were tested for inhibition of microtubule polymerization. We 
found that they acted similarly to the Vinca alkaloid vinblastine, 
a well-characterized and clinically used inhibitor of microtubule 
dynamics (Figure 2C). In addition to inhibiting gene conversion 
(Figure 2B and Supplemental Figure 2C), all tested compounds 
ulation of HDR (8–12). Mechanistically, this HDR upregulation 
may represent selective adjustment to DNA repair deficiencies 
characteristic of TNBCs. For example, in cells with BRCA1 defi-
ciency the HDR defect can be rescued by upregulation of RAD51, 
the protein with a central role in the homologous recombination 
reaction (13, 14). In fact, overexpression of RAD51 is a common 
feature of tumors from TNBC patients (13), but the mechanisms of 
HDR reactivation in TNBCs are largely unknown.
HDR inhibitors may be particularly useful for targeting upreg-
ulated HDR in TNBCs. In addition, HDR inhibitors may benefit 
tumor therapy in general, as they target S/G2 populations and 
spare normal tissues that are mostly in G1/G0 (15). S/G2 popula-
tions are often enriched within tumors as a result of chemotherapy 
or fractionated IR therapy (16).
In a search for new and more effective HDR inhibitors, we 
conducted a small-molecule screen based on potentiation of the 
cytotoxicity of the ICL-inducing agent chlorambucil. Cells defec-
tive in HDR cannot perform a recombination step of ICL repair 
and are therefore hypersensitive to DNA cross-linking agents 
(17, 18). Unexpectedly, we identified a group of tubulin binders as 
potent inhibitors of HDR. We also show that inhibition of dynamin 
2 (DNM2) — mostly known for its role in endocytosis and inter-
action with microtubules (19–21) — has a rapid and profound 
inhibitory effect on HDR capability. We considered the possibil-
ity that the DNM2-mediated role in HDR involved trafficking of 
DNA repair enzymes and studied the distribution of RAD51 within 
different cellular compartments. We found that, under unper-
turbed conditions, a considerable fraction of RAD51 in cytoplasm 
is found in vesicles tightly associated with the microtubules, and 
that DNM2 inhibition leads to reduced nuclear accumulation of 
RAD51 at the sites of DSBs.
We reasoned that if dynamin levels were important in enabling 
HDR in cells, then high HDR activity might correlate with high 
dynamin expression, which then potentially could predict the 
response to therapy of patients with TNBC/BLBC. In a retrospec-
tive analysis, we find that low DNM2 expression in tumors at the 
time of chemotherapy is associated with significantly increased 
survival of patients with TNBC/BLBC. Taken together, our results 
suggest that DNM2 and associated cell trafficking of the RAD51 
recombinase are important determinants of HDR efficiency and 
treatment outcome for patients with TNBC/BLBC.
Results
High-throughput screen to identify HDR inhibitors. HDR deficiency 
is associated with extreme sensitivity to agents that induce DNA 
ICLs (17, 18). Therefore, inhibitors of HDR are expected to fur-
ther increase the sensitivity of cells to these agents. As nitrogen 
mustards (e.g., chlorambucil) are potent inducers of ICLs, we 
monitored the increase in cellular sensitivity to chlorambucil as 
a readout to identify HDR inhibitors (Figure 1A). In secondary 
screens, 2 HDR-specific assays — for the capabilities for RAD51 
foci formation and for gene conversion — were tested. The RAD51 
foci formation assay relies on quantitation of subnuclear RAD51 
foci formed in response to DNA damage. The gene conversion 
assay uses a direct-repeat DR-GFP recombination substrate that 
quantitates HDR efficiency by detecting GFP signal in cells that 
used HDR to restore broken GFP sequence (Supplemental Fig-
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γH2AX foci (Figure 3C and Supplemental Figure 4A). Importantly, 
tubulin binders did not inhibit the nonhomologous end-joining 
(NHEJ) pathway of DSB repair (Supplemental Figure 4B). We note 
that γH2AX foci in cells treated with tubulin binders were notice-
ably larger in size (Figure 3C). To the highest dose used, they 
still contained some Rad51, suggesting that Rad51 recruitment 
to DSBs was reduced rather than abolished. In a popular view of 
Rad51 foci assembly, foci are formed from the available nuclear 
pool of Rad51 (29). Cell fractionation studies further show that the 
full response to DNA damage involves a cytoplasmic-to-nuclear 
transport of Rad51 (30) and that this process may be tubulin- 
dependent (31). Our data obtained by quantification of total Rad51 
nuclear fluorescence after treatment with tubulin binders support 
these cell fractionation studies (Supplemental Figure 4C).
from the LY290181 family also impaired IR-induced Rad51 foci 
formation (Figure 2D). Importantly, these compounds inhibited 
gene conversion and Rad51 foci at low concentrations known to 
affect tubulin dynamics but not tubulin polymerization, and at 
these concentrations they did not affect cell growth and cell cycle 
distribution (Supplemental Figure 2D and Supplemental Figure 3).
To test whether other tubulin binders affected HDR in a simi-
lar manner, we chose to investigate the effects of 3 drugs that bind 
to different microtubule domains, namely vinblastine, combreta-
statin A4 (CA4), and taxol. All 3 inhibited both gene conversion 
and the formation of IR-induced Rad51 foci (Figure 3, A and B). 
In AA8 cells costained with γH2AX, IR-induced Rad51 foci over-
lapped with γH2AX foci (Figure 3C). Treatment with tubulin bind-
ers led to a reduction in the number of cells with Rad51-positive 
Figure 1. Overview of the small-molecule screen performed to identify inhibitors of homology-directed repair (HDR). (A) Diagram of the screen. (B–E) 
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is used as a positive control for the screen. (B) 17-AAG inhibits gene conversion in the U2OS-DR-GFP 
cells. Details on gene conversion assay and quantification are provided in Supplemental Figure 1, A and C. (C) 17-AAG (100 nM) inhibits formation of Rad51 
foci in the CHO AA8 cells after 3 Gy. Images were taken at 2 hours after irradiation. Representative images from n ≥ 3 experiments are shown. Scale bars: 10 
μm. Quantification of signals is provided in Figure 2D. (D) Chlorambucil (CMBL; 5 μM) induces chromatid-type aberrations in CHO AA8 cells, and 17-AAG (150 
nM) potentiates this effect. Arrowheads point to chromatid gaps and breaks, and arrows to complex chromatid exchanges. Scale bars: 20 μm. Graph on the 
right shows quantitation for data exemplified on the left. Significance analysis: 2-way ANOVA (P = 0.0343). Distribution of chromatid-type aberrations for 
each treatment is shown in Supplemental Figure 1E. (E) 17-AAG (50 nM) increases sensitivity of CHO AA8 cells to chlorambucil, but does not affect sensitiv-
ity of HDR-deficient CHO irs1SF cells, as measured by MTS assay. Bottom: The same data as in the top panel for the irs1SF cells at lower concentrations of 
chlorambucil. Shown are means ± SDs from n ≥ 3 experiments. Significance analysis: 2-way ANOVA (P < 0.0001). *P < 0.05, ****P < 0.0001.
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ICLs induced by chlorambucil involves excision and removal of 
DNA ICLs by NER and repair of DSB intermediates by HDR (17). 
Among NER proteins only XPF and ERCC1 are involved in repair 
of ICLs (33). Cells with defects in these proteins (UV41 and UV20, 
respectively) cannot repair ICLs and therefore, like HDR mutants 
irs1SF and irs1, are extremely sensitive to chlorambucil (note the 
scale differences between panels, Figure 3, D and E). Cells defec-
tive in other NER proteins, such as XPD and XPG (UV5 and UV135 
cells, respectively), are proficient in ICL excision, but have defects 
in repair of other (less critical) types of DNA damage induced by 
chlorambucil and are therefore mildly sensitive to this drug. We 
show that tubulin binders increased sensitivity to chlorambucil 
in all mutants tested, with the exception of HDR-deficient irs1SF 
cells (Figure 3E). Importantly, the lack of effect of tubulin binders 
on sensitivity of irs1SF cells cannot be explained by the extreme 
sensitivity of these cells to chlorambucil, as tubulin binders sen-
sitized the equally hypersensitive UV41, UV20, and EM9 cells. 
Since, in contrast to all other mutants tested, there was no further 
sensitization to chlorambucil in HDR-defective cells, we conclude 
that tubulin binders potentiate chlorambucil sensitivity largely 
through impairment of HDR.
Tubulin binders have pleiotropic effects (32). Therefore, 
some of our results might have been impacted by the known 
effects of tubulin binders on cell cycle progression (32). Impor-
tantly, our data showed that the compounds from the LY290181 
family did not affect the cell cycle progression at concentrations 
used in our study, but we did observe cell cycle changes at the 
highest concentrations of CA4 and vinblastine (Supplemental 
Figure 3A). To minimize cell cycle perturbations induced by 
CA4 and vinblastine, we reduced the treatment time to 3 hours 
(which did not affect cell cycle distribution; Supplemental Fig-
ure 3B) and still observed the impaired formation of Rad51 foci 
(Supplemental Figure 4A).
As expected, vinblastine, CA4, and taxol sensitized cells to 
chlorambucil (Figure 3D). To address the possibility that tubulin 
binders may increase sensitivity to chlorambucil by interfering 
with repair of lesions other than DSBs, we used a panel of CHO 
mutant cell lines with mutations in DNA repair pathways that 
may be involved in processing chlorambucil-induced DNA dam-
age. These include mutants in nucleotide excision repair (NER) 
(with defects in XPD, XPG, XPF, and ERCC1 genes) and single- 
strand break repair (with a defect in XRCC1). Repair of DNA 
Figure 2. High-throughput chemical screen identifies tubulin binders as inhibitors of HDR. (A) A pie chart of the prescreen using the libraries of known 
compounds shows that 21% of compounds potentiating the chlorambucil effect classify as disruptors of cell trafficking. (B) Fraction of cells undergoing 
gene conversion after DSBs induced by I-SceI (GFP-positive cells) versus fraction of surviving cells. The plot identifies compounds that are able to inhibit 
gene conversion without affecting cell viability. The yellow line and the area above it show compounds (light gray symbols) for which inhibition of gene 
conversion (low fraction of GFP-positive cells) could have resulted from increased cell death associated with compound toxicity. True inhibitors of gene 
conversion are clustering in the left lower quadrant (below the yellow line), where compounds inhibit gene conversion at concentrations not affecting cell 
viability. (C) CB2, CB4, and CD3 (see Supplemental Figure 2B) inhibit tubulin polymerization similarly to vinblastine. The results for taxol are shown for 
comparison purposes. Taxol, vinblastine, CB2, CB4, and CD3 were used at 10 μM. (D) CB2, CB4, CB6, and CB13 inhibit radiation-induced Rad51 formation in 
CHO AA8 cells. CB2 and CB6 were used at 100, 200, and 400 nM each. CB4 and CB13 were used at 200, 400, and 800 nM each. 17-AAG (control) was used at 
100, 200, and 400 nM. Shown are means ± SDs from n > 2 experiments. Significance analysis: ANOVA. **P < 0.01, ****P < 0.0001.
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super-resolution microscopy analysis showed that Rad51 is asso-
ciated with tubulin in a manner suggestive of its transport along 
microtubules (Figure 4, C and D). We observed a significant 
reduction of those tubulin-associated vesicles upon knockdown 
of Rad51, thus ruling out the possibility of a staining artifact (Sup-
plemental Figure 5, A and B). We also observed the direct physical 
association of Rad51 with microtubules in a coimmunoprecipita-
tion assay (Supplemental Figure 5C).
Regulation of vesicular trafficking is strongly associated with 
tubulin acetylation, which facilitates the recruitment of molec-
ular motors and the microtubule-associated transport of cargo 
proteins (reviewed in ref. 36). Tubulin acetylation is required for 
Response to DNA damage initiates reorganization of tubulin 
and involves dynamin 2. Our data (Figures 2 and 3) suggest that 
microtubule-dependent trafficking of Rad51 may be required for 
efficient HDR. Super-resolution microscopy (34) showed that 
Rad51 was present as 2 populations: as Rad51 foci in the nucleus 
and as a separate punctate population in both the nucleus and the 
cytoplasm (Figure 4, A and B). These puncta were much smaller 
than the nuclear Rad51 foci, with an estimated maximum size 
of 280 ± 50 nm (Figure 4B). The size of these Rad51 puncta sug-
gests that they might be associated with vesicles formed during 
clathrin-mediated endocytosis (35), which mediates vesicular 
transport between different compartments within the cell. 3D 
Figure 3. Tubulin binders inhibit HDR. (A) The tubulin binders combretastatin A4 (CA4), taxol, and vinblastine inhibit gene conversion in the U2OS- 
DR-GFP cells. (B) CA4, taxol, and vinblastine inhibit formation of Rad51 foci in CHO AA8 cells at 2 hours after 3 Gy. (C) Colocalization of Rad51 and γH2AX 
foci shows that Rad51 foci are induced at DSBs and that taxol reduces Rad51 accumulation at DSBs. Scale bars: 10 μm. Insets show higher magnification of 
selected γH2AX foci. (D) CA4, taxol, and vinblastine increase the sensitivity of CHO AA8 cells to chlorambucil. (E) Taxol and vinblastine increase chloram-
bucil sensitivity of CHO mutant cells defective in nucleotide excision repair (UV5, UV20, and UV41) and base excision/single-strand break repair (EM9), but 
do not increase chlorambucil sensitivity of irs1SF cells defective in HDR. UV5, irs1SF, UV41, UV20, and EM9 cells have mutations in the XPD, XRCC3, XPF, 
ERCC1, and XRCC1 genes, respectively. Shown are means ± SDs from n ≥ 3 experiments (A, B, and D) and means ± SDs from n > 2 experiments (E; ranges 
are shown for points with 2 replicates). Significance analysis: 1-way ANOVA (A and B) and 2-way ANOVA (D and E). Drug-treated samples were compared 
with the solvent controls. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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efficient protein translocation to the nucleus in response to stress 
(37). We found that tubulin acetylation was significantly elevated 
after exposure to IR or chlorambucil in a dose-dependent man-
ner (Figure 4, E–H). Consistent with HDR taking place later in the 
cell cycle, cells in G2/M phase had the highest increase in tubulin 
acetylation signal per cell in response to DNA-damaging treat-
ment (Figure 4G). To explore this further, we searched for a tar-
get associated with vesicular trafficking and tubulin acetylation. 
Dynamin 2 (DNM2) was an obvious choice, because this GTPase 
plays key roles in receptor-mediated endocytosis and regulates 
tubulin acetylation and inhibitors of DNM2 are now readily avail-
able. DNM2 inhibitors were absent in the library that we used for 
our screen. Treatment of cells with dynasore (38), an inhibitor of 
DNM2, increased tubulin acetylation to the same level as treat-
ment with moderate doses of IR or chlorambucil (Figure 4H). 
Dynasore pretreatment did not further increase tubulin acetyla-
tion after 3 Gy (Figure 4H), suggesting that DNM2 might be act-
ing downstream of tubulin acetylation in response to DNA dam-
Figure 4. Response to DNA damage changes tubulin dynamics and involves DNM 2. (A and B) Super-resolution microscopy analysis reveals a discrete 
punctate pattern of Rad51 in cytoplasm and nucleus. Human MDA-MB-231-BR3 (A) and CHO AA8 (B) cells fixed at 2 hours after 3 Gy show Rad51 foci in the 
nucleus. Note the much smaller Rad51 dots in both the cytoplasm and the nucleus. Scale bars: 3 μm. B, right: Higher-magnification image taken from the 
same cell as in the left panel; scale bar: 1 μm. Estimation of Rad51 dot size: light gray spheres drawn around Rad51 dots have an average diameter of 280 ± 
50 nm. (C) Super-resolution microscopy images of MDA-MB-231-BR3 cells show that Rad51 associates with microtubules in unperturbed cells. Scale bar:  
3 μm. (D) 3D super-resolution analysis: images of the same Rad51 vesicles (white numbers) viewed from different angles. Numbers correspond to the same 
objects. Scale bars: 1 μm. (E) Lysine 40 (K40) α-tubulin acetylation is increased after DNA damage in human B lymphoma cell line PW. Left: Representative 
images. Scale bars: 20 μm. CMBL, chlorambucil. Right: Quantification of the fluorescence intensity per cell. (F) K40 α-tubulin acetylation increases after DNA 
damage. FACS of CHO AA8 cells fixed 2 and 4 hours after treatment with x-rays. (G) FACS analysis of K40 α-tubulin acetylation in CHO AA8 cells shows that 
G2/M-phase cells compared with G1 have the highest increase in tubulin acetylation after radiation. Left: Representative dot plots. Right: Quantification.  
Shown are means ± SDs from n = 3 experiments. (H) FACS analysis of CHO AA8 cells irradiated with 3 Gy in the absence and presence of the dynamin 2 
(DNM2) inhibitor dynasore. (E and G) Significance analysis: ANOVA. **P < 0.01, ****P < 0.0001.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 3 1 3jci.org   Volume 128   Number 12   December 2018
age. Overall, these results suggest that tubulin and DNM2 may 
increase HDR efficiency through improved trafficking of Rad51 
and possibly other HDR proteins.
Inhibition of DNM2 impairs HDR. The dynamin inhibitor dyna-
sore effectively reduced I-SceI–induced gene conversion without 
impairing NHEJ (Figure 5, A and B) and reduced the number of 
cells with Rad51-positive γH2AX foci (Figure 5, C and D), sug-
gesting that it interfered with the HDR of DSBs. Dynasore also 
increased the sensitivity of HDR-proficient cells to chlorambucil 
(Figure 5E and Supplemental Figure 6, A and B). Other inhibitors 
of DNM2 (39, 40) acted similarly to dynasore (Supplemental Fig-
ure 6C). Dynamin inhibition had no significant effect on the cell 
cycle distribution (Supplemental Figure 3B).
Dynasore, as other DNM2 inhibitors, also inhibits dynamin 
1 (DNM1) and mitochondrial dynamin (DRP1) (38–40). To rule 
out possible off-target effects of DNM2 inhibitors, we created a 
doxycycline-inducible knockdown of DNM2 in human MDA-MB- 
231-BR3 breast cancer cells. DNM2 knockdown impaired IR- 
induced Rad51 foci formation and sensitized cells to chlorambucil 
and cisplatin (Figure 5F and Supplemental Figure 7), in accord 
with our data obtained for DNM2 inhibitors.
Importantly, while dynasore effectively sensitized HDR- 
proficient AA8 and V79 cells to chlorambucil, it had no effect on 
the corresponding isogenic HDR-deficient irs1SF and irs1 cell lines 
with mutations in XRCC3 and XRCC2, respectively (Figure 5E and 
Supplemental Figure 6, A and B). These observations suggest that 
potentiation of chlorambucil sensitivity by the dynamin inhibitor 
occurred because of the impairment of HDR and not because of 
the effects on other targets of dynamin inhibition. Indeed, poten-
tiation of the chlorambucil effect by dynasore is restored in the 
CXR3 cell line (41) obtained by expression of human XRCC3 in 
XRCC3-deficient irs1SF cells (Figure 5G).
Figure 5. Inhibition of DNM2 impairs HDR. (A) Dynasore reduces gene conversion in the U2OS-DR-GFP cells. (B) Dynasore does not inhibit NHEJ, as 
measured by the appearance of CD8+GFP– cells after induction of DSB by the I-SceI enzyme in 293-1040 cells. (C) Dynasore reduces numbers of cells with 
Rad51-positive/γH2AX-positive foci after IR. CHO AA8 cells were fixed 2 hours after 3 Gy. (D) Left: Rad51 foci in the CHO AA8 cells at 2 hours after 3 Gy are 
positive for γH2AX, showing that HR repair occurs at the sites of DSBs. Right: Treatment with dynasore reduces the accumulation of Rad51 at the γH2AX 
foci. Insets show higher magnification of selected areas. Scale bars: 10 μm. (E) Treatment with dynasore increases sensitivity of HDR-proficient CHO AA8 
cells to chlorambucil, while it does not alter the sensitivity to chlorambucil in HDR-deficient XRCC3-mutant irs1SF cells. See Supplemental Figure 6A for 
the survival of irs1SF cells at lower concentrations of chlorambucil. (F) DNM2 knockdown results in increased sensitivity to chlorambucil in the human 
TNBC cell line MDA-MB-231-BR3. DNM2 knockdown was induced by the addition of doxycycline, as shown in the Western blot (right). Cells were treated 
with chlorambucil on day 5 after the addition of doxycycline. Shown are means ± SDs from n ≥ 5 experiments. (G) Correction of HDR defect in the irs1SF 
cells by introduction of XRCC3 cDNA restores both the resistance to chlorambucil and the potentiation of chlorambucil effect by inhibition of DNM2. (A–C, 
E, and G) Shown are means ± SDs (ranges) from n ≥ 2 MTS experiments. (A–C and E–G) Significance analysis: ANOVA. Dynasore-treated groups were com-
pared with no-drug group (A–C, E, and G). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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HCC1806, and metastatic mesenchymal-like MDA-MB-231-BR3 
cells) (Figure 7, B–F).
Martin et al. (13) showed that cells from BRCA1-deficient 
tumors compensate for the HDR defects by elevated RAD51 
expression; they predicted that any additional RAD51 may have 
little or no effect on tumor-derived BRCA1-deficient cells, as opti-
mum levels of RAD51 may already be reached in TNBC tumors. 
In agreement with those predictions, we show that RAD51 over-
expression in SUM149 cells has only a small effect on resistance 
to chlorambucil (dose-modifying factor [DMF] = 1.3; Figure 7B), 
compared with a much stronger effect in the U2OS cells (DMF = 
2.5; Figure 6C). Similarly, overexpression of RAD51 in other TNBC 
cell lines had no effect or only minor effects on chlorambucil 
sensitivity (DMF = 1.2 and 1, respectively; Figure 7, C and D, and 
Supplemental Figure 10).
Importantly, while RAD51 overexpression in U2OS rescued 
dynasore-induced sensitization to chlorambucil (DMF = 2.5; Fig-
ure 6C), it failed to do so in all TNBC cell lines tested (Figure 7, 
B–D, and Supplemental Figure 10). Also, both overexpression of 
RAD51 in MDA-MB-231-BR3 cells with DNM2 knockdown and 
chemical stimulation of RAD51 in MDA-MB-231-BR3 cells treated 
with dynasore failed to increase their resistance to chlorambucil 
(Figure 7, E and F, and Supplemental Figure 11). The fact that all 
our attempts to rescue dynasore-induced sensitization to chlo-
rambucil did not work in TNBC cells (while they did in other cell 
types) argues that the upregulated recombination that occurs in 
TNBC may be dependent on DNM2 to a greater extent or in addi-
tional ways compared with that in other cell types, and therefore, 
DNM2 inhibition may constitute a new way to enhance the thera-
py of TNBCs.
In vivo tests and implications for DNM2 inhibition in cancer ther-
apy. Since HDR takes place predominantly in the S/G2 phase, an 
inhibitor of HDR is expected to increase the IR sensitivity of cells 
in the S and G2 phases, largely without affecting cells in G0/G1 (15). 
This could be useful in cancer therapy, as an HDR inhibitor would 
specifically sensitize rapidly dividing tumor cells, which at any 
We reasoned that if dynasore acts through impairment of 
HDR, then selective upregulation of the HDR function should 
rescue the compound sensitivities. A moderate increase in HDR 
activity by either overexpression or stimulation of RAD51 has 
been reported to improve cell survival and to partially comple-
ment (i.e., suppress) defects in a number of different HDR genes 
that encode recombination mediator and comediator proteins 
(13, 14, 42). Hence, overexpression or stimulation of Rad51 may 
overcome impairment of HDR by dynasore. To stimulate HDR, we 
used a sulfonamido-benzamide compound, RS-1, that increases 
DNA binding and recombination activities of RAD51 by stabilizing 
RAD51 filaments and promotes resistance to chemotherapy (42, 
43). We show that treatment with RS-1 reverses both the inhibition 
of gene conversion and potentiation of chlorambucil sensitivity by 
dynasore (Figure 6, A and B). Similarly, overexpression of RAD51 
also reverses dynasore-induced sensitization to chlorambucil 
(Figure 6C and Supplemental Figure 8).
Taken together, our results show that DNM2 function impacts 
HDR. First, low or impaired DNM2 is associated with the major 
phenotypic manifestations of HDR deficiency. Second, DNM2 
inhibition does not further increase the sensitivity of HDR- 
defective hamster cell lines. Last, HDR defects stemming from 
DNM2 impairment can be rescued by direct chemical stimulation 
of RAD51 activity or by overexpression of RAD51.
RAD51 upregulation does not rescue dynamin inhibition effects 
in TNBC cells. BRCA1-mutant cells are deficient in HDR. Hence, 
we expected that, similarly to HDR-deficient XRCC2- or XRCC3- 
mutant hamster cells (Figure 5, E and G, and Supplemental Figure 
6, A and B), BRCA1-defective human cells would not be further 
sensitized to chlorambucil by inhibition of dynamin. In contrast 
to our expectations, we observed that the sensitivity to chloram-
bucil was enhanced by dynasore treatment in BRCA1-mutant 
TNBC cell lines (Figure 7, A and B, and Supplemental Figure 9). 
Overall, dynasore effectively increased the sensitivity to chloram-
bucil in cells representing different types of TNBC (as shown for 
BRCA1-mutant inflammatory breast cancer SUM149, basaloid 
Figure 6. Upregulation of HDR by direct stimulation of RAD51 activity or overexpression of RAD51 overcomes dynasore-induced sensitization to chlo-
rambucil. (A) Stimulation of RAD51 activity by RS-1 overcomes dynasore-induced inhibition of gene conversion in U2OS-DR-GFP cells. Shown are means 
and SDs from n ≥ 2 experiments. Ranges are shown for points with 2 replicates. (B) CHO AA8 cells are effectively sensitized to chlorambucil by dynasore, 
and RS-1 (7.5 μM) reverses this dynasore effect. MTS assay: Shown are means ± SDs from n ≥ 2 experiments. Ranges are shown for points with 2 replicates. 
(C) U2OS cells overexpressing the RAD51-HA construct show increased resistance to chlorambucil. While U2OS cells are effectively sensitized to chloram-
bucil by dynasore, the effect of dynasore is lost or reduced in cells overexpressing RAD51. MTS assay: Shown are means and SDs from n ≥ 3 experiments. 
See Supplemental Figure 8A for Western blots showing the overexpression of RAD51 and for the significance analysis. (A–C) Significance analysis: ANOVA. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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expression studies (see Methods). We classified each breast can-
cer patient into 1 of 3 groups based on treatment: “chemotherapy- 
treated,” “endocrine therapy–treated,” and “systemically untreat-
ed” (47). We then compared DNM2 expression in tumors between 
each group at the time of chemotherapy. Compared with the 
systemically untreated patients and those on endocrine therapy, 
chemotherapy-treated breast cancer patients had significantly 
higher DNM2 expression, likely correlating with the high aggres-
siveness of cancers for which chemotherapy is prescribed (Figure 
9A). While further separation of chemotherapy-treated patients 
into ER+ and ER– groups did not show significant differences in 
average DNM2 expression between the groups (Figure 9B), a strik-
ing difference was observed in the effects of DNM2 levels on treat-
ment outcome. In the ER– group, DNM2 expression levels below 
the median of the total breast cancer population were associated 
with highly improved post-chemotherapy outcome (P = 0.005; 
Figure 9C). Low DNM2 expression remained significantly cor-
related with good treatment outcome after adjustment for lymph 
node status, grade, and size in the Cox proportional hazards mul-
tivariate analysis (P = 0.0134). Of the clinical variables, only lymph 
node status (P = 0.0131) reached significance, while grade and size 
were not significant (P = 0.525 and P = 0.721, respectively).
The association of DNM2 expression with chemotherapy 
outcome was especially pronounced in basal-like and/or triple- 
negative breast cancers (TNBCs/BLBCs) (Figure 9D), which con-
stitute a significant fraction of ER– cancers and are associated 
with the worst prognosis. Remarkably, patients in this group with 
DNM2 levels below the median showed no relapse in a 5-year 
follow-up period, in contrast to a greater than 40% relapse rate 
for those with above-median DNM2 levels (Figure 9D). In con-
trast, the ER+ group showed no difference in survival outcome 
after chemotherapy when classified by DNM2 expression (Figure 
given time include a significant fraction of cells in the more IR- 
resistant S and G2 phases, without sensitizing the cells of the nor-
mal tissues surrounding the tumor, mostly found in G0/G1. To test 
this, we collected cells in G1, early S, and late S/G2 phases using 
mitotic shake-off as previously described (44). As predicted, 
dynasore increased the IR sensitivity of cells in the S and late S/G2 
phases, without affecting the radiation sensitivity of cells in the G1 
phase (Figure 8A). We conclude that dynasore acts as a true inhib-
itor of DSB repair pathways specific to S/G2 phase.
We then tested whether lowering DNM2 levels would increase 
chemosensitivity in vivo. For this purpose, MDA-MB-231-BR3 
cells with doxycycline-inducible expression of shRNA against 
DNM2 (shDNM2) were implanted into mammary fat pads in Nu/
Nu mice. The tumors were subjected to 2 rounds of treatment with 
cyclophosphamide, a nitrogen mustard widely used in chemother-
apy of breast cancers. We show that reduced expression of DNM2 
significantly improved tumor response to cyclophosphamide 
(Figure 8, B and C, and Supplemental Table 1). Lowering DNM2 
levels also marginally increased tumor sensitivity to cisplatin 
(Supplemental Figure 7, B and C). This effect, however, was not 
as pronounced as for cyclophosphamide, likely because DNA ICLs 
represent only a minor portion of all DNA cross-links induced by 
cisplatin (45, 46).
In summary, lowering or inhibiting DNM2 sensitized cells 
to IR and improved response to chemotherapy in the orthotopic 
breast cancer model. This suggests that high DNM2 likely inter-
feres with the response to chemotherapy of patients with late-
stage estrogen receptor–negative (ER–) breast cancers and TNBCs.
DNM2 predicts the outcome of chemotherapy of hormone receptor–
negative breast cancers. To evaluate the role of DNM2 in resistance 
to chemotherapy, we performed a survival analysis on an inte-
grated breast cancer data set derived from publicly available gene 
Figure 7. Upregulation of HDR by 
direct stimulation of RAD51 activity 
or overexpression of RAD51 fails to 
rescue dynasore-induced sensi-
tization to chlorambucil in TNBC 
cells. (A and B) Dynasore increases 
chlorambucil sensitivity of the human 
BRCA1-mutant TNBC cells HCC1937 
(A) and SUM149 (B). (B–D) Sensiti-
zation to chlorambucil by dynasore 
is not reversed by overexpression of 
RAD51-HA in TNBC cell lines SUM149 
(B), HCC1806 (C), and MDA-MB-231-
BR3 (MDA-BR3) (D). (E) Overex-
pression of RAD51-HA does not 
reduce sensitivity to chlorambucil in 
MDA-MB-231-BR3 cells with DNM2 
knockdown. (F) RS-1 does not reduce 
the sensitizing effect of dynasore in 
MDA-MB-231-BR3 cells. (A–F) Shown 
are means ± SDs (ranges) from n ≥ 3 
(A) and n ≥ 2 (B–F) MTS experiments. 
(B–F) See Supplemental Figures 10 
and 11 for Western blots showing 
RAD51 overexpression and for signifi-
cance analyses. **P < 0.01 by ANOVA. 
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cancer data set, we next analyzed breast cancer patient data from the 
highly annotated Stanford Cancer Institute Research Database. In this 
group of patients there was no difference in taxane exposure between 
the chemotherapy-treated ER+ and ER– breast cancers (Supplemen-
tal Figure 13A), making it unlikely that taxane treatment affected 
our findings for the integrated breast cancer data set. Moreover, no 
difference was observed in high-grade/low-grade tumor composi-
tion between the ER+ and ER– groups (Supplemental Figure 13B). In 
addition, we show that while the addition of taxanes to chemothera-
py was clearly beneficial for the patients with ER+ breast cancers, no 
statistical significance for taxane treatment was observed in patients 
with TNBCs (Supplemental Figure 13C). Together our retrospec-
tive analyses show that DNM2 expression predicts the response 
to chemotherapy in patients with hormone receptor–negative 
cancers, particularly TNBCs/BLBCs.
Discussion
In this study, we propose a new mechanism for the regulation 
of HDR involving microtubule-dependent molecular traffick-
ing. We identified dynamin 2 (DNM2), involved in endocytic 
transport of molecular cargo between cell compartments, reg-
ulation of microtubule dynamics (19), and interaction between 
microtubules (20, 21), as a critical factor in regulation of HDR 
activity. We propose that changes in tubulin- and DNM2-associ-
ated cell trafficking in response to DNA damage are critical for 
9C). Even in the ER+ luminal B subgroup, which may be more suit-
able for a comparison with highly proliferative ER– cancers (48), 
DNM2 expression was no predictor of treatment outcome (Sup-
plemental Figure 12). Furthermore, ER– and TNBC patients with 
longer disease-free post-chemotherapy survival showed lower 
DNM2 expression in tumors at the time of chemotherapy (Figure 
9, E and F). No such association was found for the ER+ cancers 
(Figure 9E). The data in Figure 9, E and F, are in agreement with 
the reported relapse rates for ER– breast cancers and especially for 
TNBCs, which peak between the first and third year after chemo-
therapy (6, 7). Our analysis shows that DNM2 expression at the 
time of chemotherapy in TNBCs that relapsed within the first 3 
years after chemotherapy was significantly higher compared with 
DNM2 expression in TNBCs that did not relapse until later or did 
not relapse at all (Figure 9F).
Taxanes (e.g., paclitaxel and docetaxel) have been increasingly 
used as an addition to standard chemotherapy since their approval 
as chemotherapy agents in 1995. Exposure to taxanes has been shown 
to be associated with alterations in tubulin expression (49). Although 
most of the regimen for the cohorts in our analysis did not include tax-
anes, some studies did not provide the specifics on the kinds of chemo-
therapy used. Therefore, it is possible that the increased patient sur-
vival we observed for the ER– breast cancers in Figure 9, C and D, might 
have resulted from the exposure to taxanes. To rule out any possible 
exposure to taxanes as a confounding factor in the integrated breast 
Figure 8. Inhibition of DNM2 sensitizes cells in S/G2 phase and improves tumor response to cytotoxic therapy in an orthotopic mouse model. (A) Dynasore 
increases radiation sensitivity of AA8 cells in S and S/G2 phases, but does not affect radiation sensitivity of G1-phase cells. Shown are means ± SDs (ranges) 
from n ≥ 2 MTS experiments. ANOVA: all groups were compared with the G1. **P < 0.01, ***P < 0.001. Cell cycle distribution is shown on the right. (B) DNM2 
knockdown increases tumor sensitivity to cyclophosphamide (CPX) in an orthotopic model of TNBC. MDA-MB-231-BR3 cells with an inducible DNM2 knock-
down (described in Figure 5F) were injected into mammary fat pads of female Nu/Nu mice and treated with 2 cycles of 100 mg/kg CPX on days 12, 14, and 16. 
After a 2-week break, mice were treated with CPX again (days 33, 35, and 37). DNM2 knockdown was induced by the addition of doxycycline to drinking water 
3 days before and during CPX treatment. Symbols and error bars are means ± SEMs. Significance analysis: ANOVA, *P < 0.05. (C) Same experiment as in B 
analyzed using repeated-measures method. Post hoc pairwise comparisons were performed using a Tukey adjustment for multiple comparisons. P values are 
shown at day 49. See Supplemental Table 1 for details of the significance analysis.
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therapy outcome in TNBC/BLBC patients (Figure 9, D–F). Impor-
tantly, DNM2 expression does not appear to affect the survival of 
patients treated with endocrine therapy, but is an important deter-
minant of patient survival following cytotoxic therapy, particularly 
in the ER– group (Figure 9C and Supplemental Figure 14).
RAD51 overexpression is typically observed in late-stage 
TNBCs, likely as a defense mechanism to counter high genomic 
instability (13, 14). RAD51 overexpression has been demonstrated 
to rescue proliferation defects and sensitivity to genotoxic agents in 
BRCA1- and BRCA2-defective cells (13, 50). Also, in the absence of 
BRCA/Fanconi anemia proteins, RAD51 overexpression has been 
HDR and are of specific relevance to the treatment of ER– breast 
cancers and TNBCs/BLBCs (Figure 10). Targeting DNM2 may 
therefore provide a new way of enhancing the effects of chemo-
therapy, which at present is the only option available for these 
difficult-to-treat cancers.
The unifying feature of TNBCs is that they trace their origin to 
genomic instability associated with a DNA repair (or HDR) defect, 
but regain HDR capability in late-stage, aggressive tumors (8–10, 
13). We propose that upregulated DNM2/tubulin dynamics play a 
role in the HDR reactivation in these cancers. Notably, we show 
that elevated expression of DNM2 is associated with worse chemo-
Figure 9. DNM2 expression predicts chemotherapy outcome for ER– breast cancer patients. (A) DNM2 expression in 1,000 systemically untreated 
patients, 752 patients treated with endocrine therapy, and 274 breast cancer patients treated with chemotherapy. *P < 0.05, ANOVA. (B) DNM2 expres-
sion levels are not significantly different between chemotherapy-treated ER+ and ER− tumors. P = 0.167, Mann-Whitney test. (C and D) Decreased DNM2 is 
associated with better chemotherapy outcome in ER− patients. Patients were split by median expression of DNM2 over the entire breast cancer data set 
(3,455 patients). Patients with higher than median expression of DNM2 are denoted in red, and those with lower than median expression of DNM2 are in 
black. Note the hazard ratio increase in the ER−, but not in the ER+, group. (C) Kaplan-Meier analysis of 105 patients with ER+ breast tumors treated with 
chemotherapy and 169 patients with ER− breast tumors treated with chemotherapy. (D) Kaplan-Meier analysis of 125 patients with BLBC and 76 patients 
with TNBC. (E) Longer disease-free survival after chemotherapy is associated with lower tumor DNM2 levels at the time of chemotherapy in ER− patients, 
but not in ER+ patients. Patients diagnosed with disease recurrence at the time of follow-up are designated as “Relapse,” and those remaining disease- 
free at the time of follow-up as “No relapse.” (F) Longer disease-free survival after chemotherapy is associated with lower tumor DNM2 levels at the time 
of chemotherapy in TNBC patients. Box plot: TNBCs that relapse during the first 3 years after treatment have significantly higher DNM2 than those that 
do not relapse or relapse later. (E and F) Linear regression analysis: P < 0.05 indicates that the slope is significantly non-zero. (A, B, and F) The boxes and 
whiskers contain points within the 25th to 75th and the 5th to 95th percentiles, respectively.
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cells from a Fanconi anemia group D [FA(D)] patient (58, 59). Impor-
tantly, the DNM2 message was present and not mutated in the FA(D) 
patient studied, and therefore the correction of mitomycin C hyper-
sensitivity by DNM2 could not be explained by a complementation 
of a possible defect in the DNM2 gene. The newly identified func-
tion of DNM2 in HDR suggests that in that case the correction of 
mitomycin C hypersensitivity could be due to upregulation of HDR 
by additional copies of DNM2. Separately, mutation in DNM2 has 
been shown to be associated with the neuropathic disorder Charcot- 
Marie-Tooth syndrome (CMT) (19). CMT patients display unusual 
sensitivity to both tubulin binding and ICL agents (60). Sensitivity to 
each of these classes of drugs is consistent with and can be explained 
by our findings that show that DNM2- and tubulin-associated 
trafficking of RAD51 is important in HDR.
While we favor the hypothesis that high resistance to chemo-
therapy in TNBCs results from the upregulation of HDR medi-
ated by DNM2 in late-stage TNBC, we are aware of the fact that 
elevated DNM2 also is associated with increased cell motility and 
metastasis (61), which could provide an alternative explanation for 
the increased relapse rates observed in TNBC patients with high 
DNM2. The 2 mechanisms are by no means mutually exclusive, 
as it is plausible that a tumor cell population that survives primary 
tumor chemotherapy is selected for high DNM2 expression, and is, 
therefore, more resistant to chemotherapy and more metastatic.
In summary, we found that microtubule-associated traffick-
ing affects the efficiency of HDR. Agents that disrupt microtu-
bule dynamics, including tubulin binders and DNM2 inhibitors, 
impaired all assays conducted to monitor HDR capacity. Similarly 
to tubulin-binding agents, DNM2 inhibitors sensitized cells to che-
motherapy and IR, supporting the targeted clinical application of 
these compounds as radio- and chemosensitizers. In addition, the 
fact that reduced expression of DNM2 is associated with improved 
outcome of cytotoxic therapy in patients with hormone receptor–
negative breast cancers, and specifically TNBCs/BLBCs, strongly 
suggests that DNM2 expression status could be used to stratify 
patient groups in the future.
Methods
Cell culture and transfection. All cell lines used in this study were cul-
tured for 2 passages to expand the cell population and frozen for future 
use. The CHO AA8, UV41, UV5, UV135, EM9, UV20, and HCC1806 
cells were obtained from the American Type Culture Collection and the 
SUM149 cells from Asterand Bioscience. CHO irs1SF and hamster V79 
and irs1 cells were provided by L.H. Thompson (Lawrence Livermore 
National Laboratory, Livermore, California, USA), human U2OS-DR-
GFP cells by M. Jasin (Memorial Sloan Kettering Cancer Center, New 
York, New York, USA), PW human B lymphoma cells by S.J. Knox (Stan-
ford University, Palo Alto, California, USA), MDA-MB-231-BR3 cells 
by J.E. Price (M.D. Anderson Cancer Center, Houston, Texas, USA), 
the BRCA1-deficient HCC1937 cell line and its derivatives bearing 
an empty pcDNA3.1 or a plasmid with BRCA1 cDNA (62, 63) by S.N. 
Powell (Memorial Sloan Kettering Cancer Center), and the human 
293/1040 and HT1080 cells with an inducible knockdown of RAD51 
by A. Aroumougame (University of Texas Southwestern Medical Cen-
ter, Dallas, Texas, USA). RAD51-HA expression construct was a gift 
from Z. Shen (Rutgers Cancer Institute, New Brunswick, New Jersey, 
USA). Cells were cultured in DMEM supplemented with 10% FBS and 
shown to improve the stability of stalled replication forks (51, 52). 
We hypothesize that in the absence of BRCA and other proteins that 
control recruitment of RAD51 to the sites of DNA damage and/or 
stalled replication forks (30, 51), RAD51 trafficking largely depends 
on DNM2. This may explain why overexpression of RAD51 failed to 
reverse DNM2 inhibition effects in TNBC cells (Figure 7), suggest-
ing that the upregulated recombination that occurs in TNBC may 
be dependent on DNM2 to a greater extent than in non-TNBC cells.
DNM2-associated trafficking of RAD51 provides a rational 
explanation for the recent observation that ties tumor aggressive-
ness, and specifically the basal and triple-negative status, to high 
cytoplasmic expression of RAD51 (53, 54). We note that overexpres-
sion of RAD51 may be toxic to the cells as a result of the formation 
of RAD51 complexes on undamaged DNA. In this regard, DNM2- 
mediated trafficking of RAD51 may alleviate the toxic effects of 
RAD51 overexpression and contribute to survival of TNBC cells, by 
maintaining low nuclear/high cytoplasmic levels of RAD51.
Our data may have immediate implications for improved 
treatment options for TNBC patients. Our finding of the role of 
disturbed microtubule dynamics and its negative impacts on HDR 
capacity may be useful in fine-tuning current chemo-/radiotherapy 
regimens to achieve higher cure rates. In fact, greater efficacy of 
tubulin binders when used in combination with DNA-damaging 
agents has been reported (reviewed in refs. 3, 55–57), although the 
interplay of the molecular mechanisms and associated benefits has 
not been understood.
Using dynamin inhibitors to improve chemotherapy outcome 
is an attractive possibility that might reduce systemic toxicity asso-
ciated with the use of tubulin binders. Also, since we demonstrated 
that a DNM2 inhibitor acted as a true inhibitor of HDR, by specifi-
cally sensitizing S- and G2-phase cells to IR without affecting cells 
in G0/G1, combining DNM2 inhibitors with localized radiotherapy 
might offer further advantage to reducing systemic toxicity.
The involvement of DNM2 in HDR may provide a long-awaited 
explanation for 2 observations. First, DNM2 was isolated as a 
genomic fragment that corrected mitomycin C hypersensitivity of 
Figure 10. Proposed model: DNM2 
expression differentiates between 
good and nonfavorable chemother-
apy outcomes in TNBC patients. 
Cells with high DNM2 may have more 
efficient HDR and may be selected for 
during DNA-damaging chemotherapy. 
High HDR proficiency, as well as higher 
migratory and metastatic potential in 
these cells, may constitute a mecha-
nism for resistance to chemotherapy 
in late-stage and recurrent TNBCs.
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minutes at 200 x g. Supernatants were collected as cytoplasmic frac-
tion and precleared with rabbit IgG followed by Protein A/G PLUS 
agarose beads (sc-2003, Santa Cruz Biotechnology; 1 μg of IgG and 
50 μl of Dynabeads per each milligram of lysate). Precleared lysates 
were divided for incubation with IgG and anti-Rad51 antibody (1 μg 
of antibody and 10 μl of beads per each 1 mg of protein) and incu-
bated for 4 hours, followed by 1-hour incubation with Dynabeads. 
Beads were washed 3 times with lysis buffer and resuspended in 50 
μl NuPAGE loading buffer. All procedures were performed at room 
temperature to preserve the structure of microtubules, which depo-
lymerize on ice.
Western blotting. Western blotting was performed with anti-Rad51 
(H-92, sc-8349, Santa Cruz Biotechnology, or ab63801, Abcam), 
anti–α-tubulin (05-829, DM1A, Millipore), anti-H2B (07-371, 
Upstate), anti-DNM2 (ab3457, Abcam), and anti-HA tag (clone 6E2, 
2367S, Cell Signaling Technology). See complete unedited blots in the 
supplemental material.
Cell cycle synchronization. CHO AA8 cells were synchronized in 
mitosis using mitotic shake-off procedure, as previously described 
(44). Cell cycle distribution was confirmed by FACS analysis, and cells 
were considered to be in G1 phase at 3 hours, S phase at 8 hours, and 
S/G2 at 11 hours after shake-off. Synchronized cells were pretreated for 
a half hour with 30 μM dynasore and irradiated using an X-rad 320 
irradiator (Precision X-Ray).
RNA interference. For downregulation of DNM2 by RNAi, we used 
a lentiviral RNAi system based on the BLOCK-iT system (Invitrogen) 
modified by Campeau et al. (68). The following sequences were used 
to create shDNM2 constructs: 5′-GGACTTACGACGGGAGATC-3′ 
and 5′-GACATGATCCTGCAGTTCA-3′. A doxycycline-inducible GFP 
shRNA was used as a control.
Survival analysis in integrated breast cancer data set. Gene chip 
data sets for breast cancer were identified in PubMed GEO (http://
www.ncbi.nlm.nih.gov/gds) using the keywords “breast,” “cancer,” 
and “survival.” The database was constructed as described previously 
(47). Only data sets with available raw data and clinical survival infor-
mation and including at least 30 patients were considered. Altogeth-
er, 4,142 breast cancer patients were processed; of these, 3,458 had 
relapse-free survival data. Of these, 1,000 had not received a systemic 
treatment, 274 had received chemotherapy only, and 752 had received 
endocrine therapy only. For the remaining patients, either the applied 
therapy was not documented or they received both endocrine and che-
motherapy. Chemotherapy for most of the cohorts (where described) 
included cyclophosphamide as part of the CMF regimen (cyclophos-
phamide, methotrexate, 5-fluorouracil) or FEC regimen (5-flouroura-
cil, epirubicin, cyclophosphamide). As many genes are represented 
by multiple probe sets on the Affymetrix gene chips, we selected the 
most reliable probe sets using JetSet (69). For DNM2 the probe set 
202253_s_at was used. The median expression of the genes was cal-
culated over the entire data set, and this was used as cutoff in each 
analysis. Kaplan-Meier survival plot, and the hazard ratio with 95% 
confidence intervals and log-rank P value, were calculated and plot-
ted in R using Bioconductor packages (47). For the multivariate Cox 
proportional hazards regression analysis, the clinical variables (lymph 
node status, tumor grade and size) were included.
Chemotherapy in the orthotopic xenograft model of TNBC. The 
MDA-MB-231-BR3 cells expressing doxycycline-inducible shDNM2 
or shGFP were used to create an orthotopic model of TNBC in Nu/Nu 
maintained in a humidified incubator with 5% CO2 at 37°C. Plasmid 
DNA transfections were done using LipofectAMINE-2000 (Life Tech-
nologies) following the manufacturer’s instructions.
High-throughput chemical screen. Small-molecule chemical screen-
ing was performed at the High-Throughput Bioscience Center at 
Stanford University Medical School. Screening was performed using 
libraries from ChemDiv, Specs, ChemBridge, Sigma LOPAC1280, the 
NIH Clinical Center, the National Cancer Institute Developmental 
Therapeutics Program, Microsource Spectrum, Biomol ICCB Known 
Bioactives, and Biomol FDA-approved drug library. More details are 
provided in Supplemental Methods.
Gene conversion assay. Gene conversion assay was performed as 
described in ref. 64. Briefly, U2OS-DR-GFP cells were transfected 
with I-SceI enzyme and, 6 hours after transfection, treated with chem-
ical compounds of interest. Seventy-two hours after transfection, cells 
were analyzed for the presence of GFP-expressing cells by FACS.
Nonhomologous end-joining assay. Nonhomologous end-joining 
(NHEJ) assay was performed as described in ref. 65. Briefly, we used 
a 293/1040 cell line, which stably expresses an end-joining reporter 
that contains a GFP gene flanked by I-SceI recognition sites. Down-
stream of the GFP gene the reporter contains a CD8a gene, which is 
not constitutively expressed because of the lack of an internal ribo-
some entry site. To induce DSBs, 293/1040 cells were transfected with 
the I-SceI expression plasmid. If NHEJ occurs, cells lose expression of 
GFP and gain expression of CD8, which is measured by PE-conjugated 
anti-CD8 mAb (anti-CD8–PE, BD Biosciences, 555635). Cells were 
analyzed for the loss of GFP expression and gain of CD68 expression 
by FACS 4 days after transfection with I-SceI–expressing plasmid. The 
end-joining rate was determined by counting of the percentage of 
GFP-CD8+ cells and normalizing for the transfection efficiency.
Immunofluorescence. Rad51 and γ-H2AX staining were performed 
as previously described (66). Briefly, cells were plated at 70%–80% 
confluence. Cells were pretreated with desired compounds for 30 
minutes or 1, 3, or 16 hours and irradiated with 3 Gy. Cells were fixed 
in 2% formaldehyde for 15 minutes on ice, permeabilized in 0.2% 
Triton X-100 for 15 minutes on ice, and blocked in 5% goat serum 
for 30 minutes. Cells were incubated with rabbit anti-Rad51 (clone 
H-92, sc-8349, Santa Cruz Biotechnology, or ab63801, Abcam) and/
or with anti-γH2AX (pS139, 16-202A, Millipore) antibody. Secondary 
antibodies were from Molecular Probes, Invitrogen. Tubulin stain-
ing was performed as previously described (67) with anti–α-tubulin 
(05-829, DM1A, Millipore), anti–acK40–α-tubulin (ab24610, Abcam), 
and anti–β-tubulin (F2043, Sigma-Aldrich) antibodies.
Tubulin polymerization assay. Tubulin polymerization was conducted 
in the 96-well format using HTS-tubulin polymerization assay kit BK004P 
(Cytoskeleton Inc.). Optical density at 340 nm was measured using a Tec-
an Infinite M1000 PRO microplate reader (Tecan Group Ltd.).
Super-resolution microscopy. Structured illumination microscopy 
(34) images were acquired with an OMX V4 microscope (GE Health-
care) equipped with an Olympus U-Plan Apo 60×1.42 NA oil immer-
sion objective. Image reconstruction and channel alignment process-
ing were performed with softWoRx software (GE Healthcare).
Immunoprecipitation. Cell pellets from triple-negative breast 
cancer MDA-MB-231-BR3 cells were washed twice with PBS and 
resuspended in hypotonic lysis buffer (10 mM HEPES-KOH, pH 7.5, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and protease inhibitors). 
Cells were broken down in Dounce homogenizer and centrifuged 5 
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mice. The details of tumor inoculation and monitoring are provided 
in Supplemental Methods. Treatment began when tumors reached 
60–90 mm3 and consisted of 2 cycles of cyclophosphamide or 1 cycle 
of cisplatin (300 mg/kg/cycle or 16 mg/kg/cycle, respectively). To 
induce DNM2 knockdown, doxycycline was given 3 days before and 
during cyclophosphamide or cisplatin administration. Cisplatin was 
given by i.p. injections on days 11, 13, 15, and 17 after tumor cell inoc-
ulations. Cyclophosphamide cycle was composed of 3 i.p. injections 
given every other day followed by a 2-week rest period.
Statistics. The specific details of statistical tests and number of sam-
ples and experimental repeats are included in the figure legends. A Stu-
dent’s t test was used for comparing 2 groups. ANOVA models were used 
for comparing 3 or more groups with post hoc testing for pairwise com-
parisons. A Tukey adjustment was applied in testing all possible pairwise 
comparisons, and a Dunnett’s adjustment was applied in comparing 
treatment groups with a control. To find interactions between com-
pounds or to compare dose-response curves, we used 2-way ANOVA. 
The in vivo experiments were randomized and analyzed in a general-
ized linear model to account for the within-mouse correlations. The 
treatment groups were compared across time, and at each time point 
and post hoc, pairwise comparisons were done with a Tukey adjust-
ment. All tests were 2-sided with an α level of 0.05; and all tests were 
performed in Prism (GraphPad Software) or SAS version 9.4 (SAS Insti-
tute Inc.). A P value less than 0.05 was considered significant.
Study approval. All animal procedures were approved by Stanford 
University’s Administrative Panel on Laboratory Animal Care.
Additional methods are provided in Supplemental Methods.
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